Build Generational Wealth with
AlphaMadera's AI-Driven Investment Intelligence

Institutional-grade analytics, real-time data, and AI research tools — built for investors who think in decades, not days.

Ask Compass anything about the market — earnings, filings, or strategy — in plain English.

Real-time institutional data AI that reads filings & transcripts Built for decades, not days
or search any ticker above
Editorial illustration: PRIMARY SUBJECT — this editorial photo illustrates a story about State Street SPDR S&P 500 ETF, a Asset Management compa
AlphaBlog

Markets Want Details, Not Summit Theater

Stocks are modestly higher as investors lean into the Trump-Xi meeting as a de-escalation setup. The real question is whether next week brings tariff and export-control changes that alter cash flows, not just headlines.

Read more →

Market News

Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement

Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement

Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. PM359 is positioned for a potential BLA submission for CGD in 1H 2027, leveraging RMAT and other regulatory designations. Initial clinical data from global phase 1/2 studies of PM577a [WD] and PM647 [AATD] are expected in 2027, targeting significant market opportunities.

Sep 25, 2026 12:00 PM • seekingalpha.com
Trump, Xi wrap state visit centered on spectacle over substance. Here are the top takeaways

Trump, Xi wrap state visit centered on spectacle over substance. Here are the top takeaways

President Trump and leader Xi agreed to extend a trade truce that was due to expire in November and avoided agreement on addressing AI threats. Xi's visit to Washington spanned three days and was highly televised in China but not in the U.S. after Trump banned three news outlets from the White House last week and the broadcast press pool that would have covered the event lapsed.

Sep 25, 2026 10:52 AM • cnbc.com
Jefferies: Private Credit Losses And Slow Trading May Hit Q3 Results

Jefferies: Private Credit Losses And Slow Trading May Hit Q3 Results

Jefferies Financial Group Inc. remains a Hold as private credit overhang and earnings volatility persist, despite shares trading at 1.4x tangible book value. JEF faces ongoing legal and credit risks from First Brands and Radiant World exposures, with $1.2 billion at risk and lawsuits likely to drag on. Asset management results are pressured, with Point Bonita winding down and management fees dropping sharply; investment banking remains a relative bright spot.

Sep 25, 2026 10:21 AM • seekingalpha.com

Stock News